Description of patients with known aGvHD grade
| Factors influencing GvHD . | No. of patients (%) . | |||
|---|---|---|---|---|
| Before 1993 . | 1993-1996 . | After 1996 . | Total . | |
| All patients | 1879 (45) | 1260 (30) | 1035 (25) | 4174 (100) |
| Sex | ||||
| Male | 1095 (58) | 734 (58) | 602 (58) | 2431 (58) |
| Female | 784 (42) | 526 (42) | 433 (42) | 1743 (42) |
| Age, y | ||||
| Younger than 20 | 163 (9) | 85 (7) | 80 (8) | 328 (8) |
| 20-40 | 1241 (66) | 652 (52) | 498 (48) | 2391 (57) |
| Older than 40 | 475 (25) | 523 (41) | 457 (44) | 1455 (35) |
| Donor-recipient sex combination | ||||
| Donor (F) + recipient (M) | 470 (25) | 310 (25) | 273 (26) | 1053 (25) |
| Other | 1409 (75) | 950 (75) | 762 (74) | 3121 (75) |
| Interval between diagnosis and transplantation | ||||
| Shorter than 12 mo | 931 (50) | 771 (61) | 705 (68) | 2407 (58) |
| 12 mo or longer | 948 (50) | 489 (39) | 330 (32) | 1767 (42) |
| aGvHD prevention | ||||
| T-cell depletion | 691 (52) | 173 (24) | 110 (14) | 974 (34) |
| Cyclo alone | 130 (10) | 53 (7) | 17 (2) | 200 (7) |
| Cyclo + mtx | 487 (36) | 451 (61) | 364 (46) | 1302 (45) |
| Other | 32 (2) | 56 (8) | 307 (38) | 395 (14) |
| Source of stem cells | ||||
| BM | 1879 (100) | 1132 (90) | 618 (60) | 3629 (87) |
| PB | 0 (0) | 128 (10) | 417 (40) | 545 (13) |
| Factors influencing GvHD . | No. of patients (%) . | |||
|---|---|---|---|---|
| Before 1993 . | 1993-1996 . | After 1996 . | Total . | |
| All patients | 1879 (45) | 1260 (30) | 1035 (25) | 4174 (100) |
| Sex | ||||
| Male | 1095 (58) | 734 (58) | 602 (58) | 2431 (58) |
| Female | 784 (42) | 526 (42) | 433 (42) | 1743 (42) |
| Age, y | ||||
| Younger than 20 | 163 (9) | 85 (7) | 80 (8) | 328 (8) |
| 20-40 | 1241 (66) | 652 (52) | 498 (48) | 2391 (57) |
| Older than 40 | 475 (25) | 523 (41) | 457 (44) | 1455 (35) |
| Donor-recipient sex combination | ||||
| Donor (F) + recipient (M) | 470 (25) | 310 (25) | 273 (26) | 1053 (25) |
| Other | 1409 (75) | 950 (75) | 762 (74) | 3121 (75) |
| Interval between diagnosis and transplantation | ||||
| Shorter than 12 mo | 931 (50) | 771 (61) | 705 (68) | 2407 (58) |
| 12 mo or longer | 948 (50) | 489 (39) | 330 (32) | 1767 (42) |
| aGvHD prevention | ||||
| T-cell depletion | 691 (52) | 173 (24) | 110 (14) | 974 (34) |
| Cyclo alone | 130 (10) | 53 (7) | 17 (2) | 200 (7) |
| Cyclo + mtx | 487 (36) | 451 (61) | 364 (46) | 1302 (45) |
| Other | 32 (2) | 56 (8) | 307 (38) | 395 (14) |
| Source of stem cells | ||||
| BM | 1879 (100) | 1132 (90) | 618 (60) | 3629 (87) |
| PB | 0 (0) | 128 (10) | 417 (40) | 545 (13) |
Cyclo indicates cyclosporin A; mtx, methotrexate; BM, bone marrow; and PB, peripheral blood.